RxDoctor Payments Data

Ari Kravitz

Family · Phoenix, AZNPI 1598408437

Payments from drug & device makers

$4,524in general payments, 2019–2025

Across 216 payments — averaging $20.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$2K
  • Viiv Healthcare Company$849
  • Merck$545
  • EMD Serono, Inc.$257
  • Johnson & Johnson$190
  • Napo Pharmaceuticals Inc$171
  • plus $650 from 10 others

What the payments were for

  • Food & beverage$4,40797%
  • Education$1173%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,524 in reported general payments places this provider in the 90th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Medicare billing

Part B allowed, 2024
$5,918
Medicare patients
26
Services billed
68

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala89$382,780
CabenuvaCabotegravir/Rilpivirine42$293,339
DovatoDolutegravir Sodium/Lamivudine42$134,826
DescovyEmtricitabine/Tenofov Alafenam33$78,384
PrezcobixDarunavir/Cobicistat19$65,014
OdefseyEmtricitab/Rilpiviri/Tenof Ala17$59,681
TivicayDolutegravir Sodium20$48,670
IsentressRaltegravir Potassium13$26,936
PifeltroDoravirine12$23,216
JardianceEmpagliflozin21$13,033
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$11,201
Testosterone16$2,362
Testosterone Cypionate24$627
Albuterol Sulfate HfaAlbuterol Sulfate27$396
Losartan Potassium42$349

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyCabenuva, Dovato, Tivicay$849$476,835104 claims
GileadBiktarvy, Descovy$1,862$461,164122 claims
Johnson & JohnsonPrezcobix$190$65,01419 claims
MerckIsentress, Pifeltro$545$50,15125 claims
GSKTrelegy Ellipta$17$11,20117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,119 family providers in Arizona.

Other family in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →